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DIRECT MEDICAL COSTS OF OSTEOARTHRITIS IN SPAIN
Darba J1, Restovic G2, Kaskens L2
1Universitat de Barcelona, Barcelona, Spain; 2BCN Health, Barcelona, Spain
OBJECTIVES: Osteoarthritis (OA) is the most common musculoskeletal disease, with 
around 1.6 million patients in Spain. The aim of this study was to determine health 
care resource utilization and direct medical costs of patients suffering OA of the hip, 
knee and wrist in Spain in 2009. METHODS: A cost-of-illness analyses was performed 
to estimate direct medical costs of patients suffering OA. Prevalence data on OA by 
the Spanish Society of Rheumatology showed a value of 18% for the Spanish popula-
tion. a semi-structured questionnaire was sent to rheumatologists to collect data on 
health care resource utilization and costs. Inpatient costs were considered from the 
perspective of the public health care system. Direct medical costs included were 
ambulatory, diagnostic tests, physiotherapy, surgery, drug and administration costs. 
All costs referred to 2009. RESULTS: Patients diagnosed with OA of the hip, knee 
and wrist in Spain were estimated to be 1.6 million in 2009. Total medical costs for 
the Health Care System resulted as following: drug use 95c million, health care person-
nel 251c million, diagnostic tests 20c million, physiotherapy 93c million, surgery 105c 
million and adverse effects due to OA medication 25c million. Due to demographic 
changes and increasing prevalence, the number of patients is estimated to grow to 1.7 
million with total costs of 717c million in 2014. CONCLUSIONS: Direct medical 
costs for OA were estimated at 598c million for Spanish patients in 2009. Health care 
personnel represented 43% of the total direct medical costs. Aging of the population, 
development of new drugs and increasing patient expectations are likely to increase 
the future economic impact of OA, which remains a major public health burden.
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HIP FRACTURES IN THE ELDERLY: COST OF ILLNESS STUDY UNDER A 
PUBLIC HOSPITAL PERSPECTIVE IN RIO DE JANEIRO, BRAZIL
Fernandes RA1, Takemoto ML2, Araujo D2, Sauberman MV3
1Instituto Nacional de Ciência e Tecnologia para Avaliação de Tecnologias em Saúde (IATS), 
Rio de Janeiro, RJ, Brazil; 2State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; 
3Hospital Municipal Lourenço Jorge, Rio de Janeiro, RJ, Brazil
OBJECTIVES: To assess direct medical costs associated to hospital treatment of hip 
fractures in the elderly in a public hospital in Rio de Janeiro, Brazil and their association 
with demographic and clinical variables. METHODS: Observational, prospective study 
to assess resource utilization and direct medical costs associated to elderly hip fracture 
hospitalization in 2007 and 2008, under the health care provider perspective. a standard 
data collection instrument was used to register identiﬁ ed resources during prospective 
medical charts review. The resource utilization was converted into Brazilian Real (BRL), 
based on 2010 prices. Descriptive analysis of costs and resource utilization and their 
association with clinical and demographic variables were performed. RESULTS: Eighty 
two patients were included, 81.7% female, mean age of 76.96 years, hospitalization 
mean time of 12.66 days. Median total costs per patient were 3,064.76 BRL (IC95%: 
2,817.63–3,463.98). Clinical hospitalization and surgical procedure were responsible 
for 65.61% and 24.94% of costs, respectively. Median costs for patients submitted to 
surgical procedure until the fourth day of hospitalization were lower than median costs 
for patients submitted after the fourth day (2,136.45 BRL and 3,281.45 BRL, respec-
tively, P < 0.00001). A signiﬁ cant difference in average costs per type of surgical pro-
cedure was also observed. Variables sex, age over 80 years, fracture site and presence 
of cardiovascular disease were not associated with statistically signiﬁ cant differences in 
total costs. CONCLUSIONS: Clinical hospitalization and surgical procedure were the 
main cost components observed. Higher cost associated to inpatient treatment of hip 
fractures in patients who performed surgery after the fourth day of hospitalization added 
to available evidence about an increased risk of mortality after this period reinforce the 
need of priority establishment to treat elderly patients with hip fracture.
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ANALYSIS OF DIRECT MEDICAL AND NON-MEDICAL COSTS FOR CARE 
OF RHEUMATOID ARTHRITIS PATIENTS USING LARGE COHORT 
DATABASE, IORRA
Igarashi A1, Kikuta K1, Tanaka E2, Hoshi D2, Inoue E2, Seto Y2, Nakajima A2, 
Momohara S2, Taniguchi A2, Yamanaka H2, Tsutani K1
1Tokyo University Faculty of Pharmacy, Tokyo, Japan; 2Tokyo Women’s Medical University, 
Tokyo, Japan
OBJECTIVES: To examine annual direct medical & non-medical cost in large-scale 
rheumatoid arthritis (RA) patient cohort (IORRA) in Japan. METHODS: From 
patients’ perspective, we calculated direct medical (out-of-pocket costs to hospital & 
pharmacy and cost for complementary & alternative medicine(CAM)) and non-med-
ical costs (caregiving, transportation,self help devises, house modiﬁ cation) of RA 
patients, participants of the 15–17th IORRA Studies in Oct. 2007- Oct. 2008. We 
also assessed correlations between these costs and RA diseaseactivity, disability level 
and QOL. RESULTS: Data from 5204 RA patients were extracted. Annual direct 
medical costs were JPY132,000 (out-of-pocket to hospital, USD1 = JPY90), JPY84,000 
(out-of-pocket to pharmacy) and JPY 146,000 (CAM)), respectively. Annual direct 
non-medical costs were JPY105,000 (caregiving), JPY22,000 (transportation), 
JPY30,000 (self help devises) JPY188,000 (house modiﬁ cation), respectively. Consid-
ering utilization rates for each cost component (hospital/pharmacy: 100%, CAM: 
31.6%, caregiving: 10.5%, transportation: 100%, self help devices: 21.4%, house 
modiﬁ cation: 21.4%). We assumed that annual medical/non-medical cost per RA 
patient was JPY264,000 and JPY61,000, respectively. These costs increased progres-
sively with worsening RA diseaseactivity, disability level, or QOL. For example, 
patients with lower Eq-5D score (less than 0.5) spent more money than those with 
higher one (more than 0.8). Average medical and non-medical costs among them were 
JPY 30,802 vs. JPY17,887 and JPY229,519 vs. JPY19,536, respectively. CONCLU-
SIONS: Heavy economic burden lies in RApatients and grows heavier as the disease 
state is exacerbated using IORRA database. The results also suggest that the increase 
in medical/non-medical cost may be suppressed by proactively controlling RA.
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COST-EFFICACY ANALYSIS OF TNF ALPHA ANTAGONISTS IN THE 
TREATMENT OF RHEUMATOID ARTHRITIS
Dominguez Gil-Hurlé A1, Costi Ruiz M2, Campo Sien C2
1Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y León, Spain; 2Abbott 
Laboratories, Madrid, Spain
OBJECTIVES: Estimate the efﬁ ciency of Tumor Necrosis Factor α (TNFα) antagonists 
in moderate to severe rheumatoid arthritis (RA). METHODS: The analysis, performed 
from the Spanish Health Care System perspective, considers the annual cost of the drugs, 
and their efﬁ cacy, measured through the number needed to treat (NNT) to gain an 
additional patient who achieves ACR20, ACR50 and ACR70 response. Drug costs were 
obtained from a Spanish database. Data relative to efﬁ cacy was derived from a meta-
analysis, which evaluated the anti–TNFα drugs adalimumab (ADA), etanercept (ETA), 
and inﬂ iximab (INF). Efﬁ ciency was estimated in terms of incremental cost-efﬁ cacy 
ratios (ICER). RESULTS: Annual treatment cost per patient-year with ADA, ETA and 
INF is of 13.116c, 12.314c, and 14.047c, respectively. Applying the: 1) ACR20 criteria, 
the NNT with ADA, ETA, and INF were 4.2 (95% CI, 3.4–5.3), 6.5 (5.2–8.8), and 4, 
5(3.4–6.8), respectively; 2) the ACR50 criteria, the NNT with ADA, ETA, and INF were 
4.1 (3.4–5.1), 4.4 (3.7–5.5), and 6.6 (4.7–11.5), respectively; and 3) the ACR70 criteria, 
the NNT with ADA, ETA, and INF were 5.7 (4.6–7.5), 6.8 (5.3–9.4), and 8.6 (5.8–
16.7), respectively. The incremental annual cost per additional patient who achieves 
ACR20 response with ADA, ETA, and INF is of c54.871 (95% CI, c45,080–70,095), 
c80,598 (c64,288–c107.999), and c63,329 (c47,268c–c95,923), respectively. The 
incremental annual cost per additional patient who achieves ACR50 response with 
ADA, ETA, and INF is of c53,368 (c44,407–c66,828), c54,596 (c45,691–c67,813), 
and c93,072 (c65,451–c161,030), respectively. The incremental annual cost per addi-
tional patient who achieves ACR70 response with ADA, ETA, and INF is of c74,537 
(c59,759–c99,025), and c83,661 (c65,481–c115,815), c120,652 (c81,242–c34,319), 
respectively. CONCLUSIONS: The incremental cost per patient who achieves an 
ACR20, ACR50, and ACR70 response is lower with ADA, though quite similar to ETA, 
being with both (ADA and ETA) lower than with INF, in the Spanish setting.
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RETROSPECTIVE CHART REVIEW TO ASSESS COSTS RELATED TO 
OSTEOPOROTIC FRACTURES IN SLOVENIA AND SERBIA
Wladysiuk M1, Wilk D1, Jedynasty K2, Bumbasirevic M3, Kozlevcar Zivec M4
1HTA Consulting, Krakow, Poland; 2Amgen GmbH, Headquarters Ofﬁ ce for CEE, Vienna, 
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OBJECTIVES: To evaluate direct medical costs of treatment for osteoporotic fractures 
in Slovenia and Serbia from a public payer and patient perspective directly after fracture 
and up to 1 year follow-up. METHODS: A medical chart review, examining medical 
resources used to treat the 3 most common osteoporotic fractures (proximal femur, 
vertebral and distal radius) in the ﬁ rst year after the event. Collection of data from 1 
osteoporotic center in Slovenia and 3 in Serbia was carried out by local investigators 
between December 2009 and March 2010. The treatment costs for each fracture type 
from the public payer and patient perspective were calculated. The analysis was divided 
into 2 parts: intervention directly after the fracture (including cost of hospitalization, 
ambulatory visits, procedures, examinations, and medications) and follow-up for up to 
1 year after the event (including costs of hospitalization, outpatient visits, examinations, 
rehabilitation, medications and devices). RESULTS: A total of 240 patients aged >50 
years with low-trauma fractures occurring within 5 years before study initiation were 
included. Average annual costs of treatment of a proximal femur fracture in Slovenia 
were estimated at c4727 (costs directly after fracture = c4088 and follow-up period = 
c639) and in Serbia c3002 (c2359 and c642, respectively). The cost of treatment of a 
vertebral fracture was c4319 in Slovenia (c3762 and c557, respectively) and in Serbia 
c390 (c103 and c287, respectively). Treatment of the distal radius fracture was c1567 
in Slovenia (c1046 and c521, respectively) and in Serbia c163 (c57 and c106, respec-
tively). CONCLUSIONS: Treatment of proximal femur fractures vs. vertebral and distal 
radius fractures generated the highest costs. The treatment costs were signiﬁ cantly higher 
in Slovenia compared with Serbia. Large disparities between the costs of hospitalization 
in both countries were the major reason for the observed differences.
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MEDICINE TREATMENT COST OF RHEUMATOID ARTHRITIS BEFORE 
AND AFTER TREATMENT WITH BIOLOGICAL DRUGS
Roux I, Lubbe M, Burger JR, Lamprecht J
North-West University, Potchefstroom, South Africa
OBJECTIVES: To investigate the medicine treatment cost of rheumatoid arthritis (RA) 
before and after treatment with biological drugs in the private health care sector of 
South Africa. METHODS: A quantitative retrospective drug utilization review was 
performed on medicine claims data of a pharmacy beneﬁ t management company 
(PBM) in South Africa. Data for a four-year period (January 1, 2005 to December 31, 
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2008) were used to determine the medicine treatment cost of 141 RA patients before 
and after treatment with biological drugs (namely inﬂ iximab, adalimumab and etan-
ercept). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 
8.27505 (2008)]. RESULTS: Biological drugs represented 81.43% of the total medi-
cine treatment cost of RA patients (n = R25,432,294.04). Other medication (excluding 
biological drugs) prescribed to RA patients before starting with biological items rep-
resented 8.86% (n = R2 254 330.44) of their total medicine treatment cost; those 
prescribed after treatment with biological drugs, represented 3.91% (n = R992,533.62). 
The number of prescriptions for other medication (excl. biological drugs), decreased 
from the period before to the period after treatment with biological drugs from 6271 
to 2120. The average number of the other medicine items (excl. biological) per pre-
scription decreased from 2.79 ± 2.30 before to 2.35 ± 1.86 after treatment with 
biological drugs. The average cost per biological drug (R8 073.61 ± 2 210.46) was 
practically signiﬁ cantly (d > 0.8) higher than the average cost of other medication 
prescribed before (R128.45 ± 155.93) and after (R198.66 ± 888.31) treatment with 
biological drugs. CONCLUSIONS: Although biological drugs used in the treatment 
of RA are very expensive, it seems that the number of other medication prescribed to 
RA patients, as well as the average number of items per prescription decreased after 
treatment therewith. Further research is needed to investigate future medicine treat-
ment cost of RA patients treated with biological drugs.
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THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND 
INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID 
ARTHRITIS
Lawson RW1, Heatley RM1, Johnson KI1, Khandker RK2, Singh A2
1Complete Market Access, Macclesﬁ eld, UK; 2Pﬁ zer, Collegeville, PA, USA
OBJECTIVES: To review and analyze evidence on the changes in dose of adalimumab, 
etanercept and inﬂ iximab over time in adult patients with rheumatoid arthritis (RA) 
and the associated impact on treatment costs. METHODS: MEDLINE, EMBASE and 
NHS-EED were systematically searched to identify English language randomised con-
trolled trials, cohort studies and observational studies published between January 
1993 and December 2009. Conference abstracts were also hand searched from 
EULAR (2002 onwards) and ACR (2006 onwards). Studies were selected using pre-
deﬁ ned criteria, using two independent reviewers. Data pertaining to dose change were 
then analyzed through pair-wise, random effects meta-analyses carried out in a fre-
quentist framework with heterogeneity assessed using the I2 statistic. Associated cost 
data were extracted and the impact of change in dose on cost was investigated. 
RESULTS: Forty-ﬁ ve articles met the selection criteria with 23 containing dose change 
data and 26 containing cost data. a signiﬁ cantly greater proportion of patients on 
inﬂ iximab had a dose escalation compared to those on etanercept (odds ratio 0.17 
95% CI 0.07, 0.43; P < 0.001) or adalimumab (odds ratio 0.25 95% CI 0.2, 0.3; P 
< 0.001). On average, 43.3% of inﬂ iximab patients, 7.3% of etanercept patients and 
10.9% of adalimumab patients had their dose increased. RA related costs were on 
average 36% higher in patients who had their inﬂ iximab dose increased compared to 
4% in patients on etanercept. No suitable data for adalimumab were available. 
CONCLUSIONS: A signiﬁ cantly greater proportion of inﬂ iximab patients required 
dose escalation compared to etanercept and adalimumab patients. There is some 
evidence to suggest that the escalation in dose required to maintain clinical beneﬁ t, 
results in substantially higher costs of treating RA.
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MICRO-COSTING ANALYSIS AND TARIFF COMPARISON: THE 
INTERSPINOUS PROCESS DEVICE CASE
Beccagutti G1, Corbo M1, Pantaleoni M2, Surace MF3
1Medtronic Italia, Sesto San Giovanni, Milan, Italy; 2IMS Health S.p.A, Milano, Italy; 3Ospedale 
di Circolo—Fondazione Macchi, Varese, Italy
OBJECTIVES: In Italy the recent update of the DRG system has led to evaluate the 
effect on the diffusion of new therapies. The Interspinous Process Device (IPD) implan-
tation represents an innovative strategy for different degenerative spinal pathologies 
with potential clinical and economic advantages. The aim of this study is to evaluate 
the hospitalization costs for IPD procedure according to a micro-costing approach and 
to compare it with current regional DRG tariffs. METHODS: The project, conducted 
from the hospital perspective, is performed in one pilot centre (Varese hospital), 
regional benchmark for this kind of procedure in which learning curve is considered 
completed. The cost analysis is based on the clinical pathway drawn up from the 
information provided by the medical team. Resource use including staff time, diag-
nostic tests, drugs, consumables and technology equipment utilization are collected 
from interviews to the team. Operating room costs, administrative and general costs 
and follow up hospital resource consumption are derived from hospital accounting 
data. Unit costs are collected either from hospital accounting or regional tariffs for 
specialist services. RESULTS: The total average cost estimated for a patient submitted 
to an IPD implantation is c5644, with an average LOS of 2.7 days. The average cost 
for the implantation of 1 IPD is c4515, value assigned to increase to c7087 for mul-
tilevel approaches with the implantation of 2 devices in the same procedure (42% of 
cases). Excluding general costs and the number of IPDs implanted, the main key cost 
driver are consumables and devices (62%), and operating room costs (16%). CON-
CLUSIONS: The regional tariff of the DRG related to this procedure (Lombardia 
Region, DRG 500, version 24) does not cover the hospitalization costs estimated, 
especially for the multilevel approaches. This leads to consider the effects of current 
reimbursement on the adoption of innovative therapy.
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COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF 
PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS 
DMARD THERAPY IN MEXICO
Carlos F1, Aguirre A2, Peláez-Ballestas I3
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, inﬂ ammatory 
disease that affects physical functioning and quality-of-life and is associated with 
premature mortality and substantial economic burden. We aimed to assess cost-
effectiveness of tocilizumab added to disease-modifying antirheumatic drugs 
(DMARD) in patients with active RA despite DMARD therapy from the Mexican 
public health care system perspective. METHODS: Two models were designed to 
compare tocilizumab 8 mg/kg every 4 weeks; inﬂ iximab 3 mg/kg (weeks 0, 2, 6, 14 
and 22); etanercept 25 mg twice a week and adalimumab 40 mg every other week. 
First model included only 6-month acquisition costs of drugs and infusion-related cost 
for inﬂ iximab and tocilizumab; the second was a Markov model with four states 
deﬁ ned according to Disease Activity Score (DAS-28). Indirect comparison techniques 
were needed to adjust American College of Rheumatology (ACR) responses rates 
found in 10 clinical trials with biological agents. ACR70 at week 24 and overall days 
spent in remission during 5 years were main outcomes. Unit costs of medications were 
gathered from public bids; an expert panel was constituted to estimate 3-month 
resource use by health state. All costs are expressed in 2009 US dollars. RESULTS: 
First six-month costs were lower with tocilizumab (USD$4418) than with etanercept 
(USD$5,020), inﬂ iximab (USD$5484) and adalimumab (USD$5655). Adjusted 
ACR70 response rate was higher for tocilizumab than for anti-tumor necrosis factor 
(TNF) agents: 26% vs. 19%, 18% and 12% for adalimumab, etanercept and inﬂ ix-
imab, respectively. Markov model estimates show savings of USD$623 up to 
USD$1321 per patient treated with tocilizumab instead of anti-TNF. Tocilizumab was 
also associated with mean gains of 9, 12 and 20 days in remission compared to 
etanercept, adalimumab and inﬂ iximab. CONCLUSIONS: When used instead of anti-
TNF agents, add-on treatment with tocilizumab brings both health beneﬁ ts and cost-
savings for RA patients with inadequate response to previous DMARD therapy.
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COST-EFFECTIVENESS OF GOLIMUMAB IN PSORIATIC ARTHRITIS 
FROM THE UK PAYER PERSPECTIVE
Cummins E1, Asseburg C2, Prasad M3, Buchanan J4, Punekar Y5
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BACKGROUND: Golimumab is a novel TNF-α inhibitor licensed to treat patients with 
active PsA. Although its clinical efﬁ cacy has been proven in clinical trials, its cost-
effectiveness is yet to be established. OBJECTIVES: To estimate the cost-effectiveness 
of golimumab among patients with active PsA from the UK NHS perspective. 
METHODS: A decision analytic model was used to simulate progression of a hypotheti-
cal cohort of active PsA patients on golimumab and other TNF-α inhibitors as well as 
palliative care. The clinical evidence was derived from clinical trials of TNF-α inhibitors 
and compared using mixed treatment models. The primary outcome measure was 
quality adjusted life-years (QALYs) estimated based on change in Health Assessment 
Questionnaire (HAQ) and Psoriasis Area Severity Index (PASI) from baseline. The 
annual acquisition cost of golimumab was assumed to be identical to annual cost of 
other subcutaneous TNF-α inhibitors. The resource use costs and outcomes were dis-
counted at 3.5% over a period of 40 years. The uncertainty surrounding important 
variables was further explored using probabilistic sensitivity analyses (PSA). RESULTS: 
TNF-α inhibitors were signiﬁ cantly superior to palliative care but comparable to each 
other on Psoriatic Arthritis Response Criteria (PsARC), HAQ and PASI response. The 
incremental cost-effectiveness ratio (ICERs) for golimumab compared to palliative care 
was £16,811 for PsA patients and £16,245 for a subgroup of PsA patients with signiﬁ -
cant psoriasis. At an acceptability threshold of £30,000 per QALY, the probability of 
golimumab being cost-effective is 89%. CONCLUSIONS: Once monthly, golimumab 
is a cost-effective treatment alternative for patients with active PsA. With its patient 
focussed attributes, golimumab is likely to offer additional choice in PsA treatment.
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COST-EFFECTIVENESS OF TERIPARATIDE IN PATIENTS WITH 
GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN SWEDEN
Smolen LJ1, Gregor Z2, Barrett A3, Myrén KJ4, Toll A5
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OBJECTIVES: Glucocorticoid induced osteoporosis is the most common cause of 
secondary osteoporosis. The objective of this study was to estimate the cost-effective-
ness of teriparatide in patients with Glucocorticoid induced osteoporosis in Sweden. 
METHODS: A cost-effectiveness analysis was developed to evaluate the direct medical 
and tertiary care costs and clinical outcomes of an 18-month regimen of daily teripa-
ratide in patients with glucocorticoid induced osteoporosis (GIO). a Monte Carlo 
simulation was used to model the cost and effects of a simulated cohort of 100,000 
patients with GIO treated with teriparatide compared to no teriparatide treatment. 
The model simulated the course of events in 6-month cycles in individual patients over 
a lifetime horizon. During each cycle the patients were at risk of experiencing clinical 
